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Background: Acute kidney injury in patients with acute pancreatitis carries a poor prognosis. Hemolytic uremic
syndrome (HUS) is characterized by non-immune hemolytic anemia, thrombocytopenia, and renal failure caused by
platelet thrombi in the microcirculation of the kidney, and though rare in adults it is associated with high mortality
and a high rate of chronic renal failure.
Case presentation: Herein, we report a case of alcohol-induced acute pancreatitis in a 38-year-old Chinese female
complicated by HUS. Her renal function progressively deteriorated in 2 days, and daily continuous renal replacement
therapy (CRRT) was thus performed for a total of 13 treatments. She also received intermittent transfusions of fresh
frozen plasma. Her renal failure was successfully managed, with subsequent return of normal renal function. She was
discharged 1 month after admission and follow-up at 3 months revealed normal urea and creatinine.
Conclusion: CRRT was shown to be useful for the treatment of HUS following acute pancreatitis. Prior case reports and
our case should remind clinicians that HUS is a possible complication of acute pancreatitis. This study highlights the
importance of early diagnosis and prompt initiation of CRRT to prevent mortality and improve outcomes.
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The incidence of acute kidney injury in patients with acute
pancreatitis ranges from 14-42%, and carries a poor prog-
nosis [1]. Hemolytic uremic syndrome (HUS) as a result of
alcoholic pancreatitis is seldom encountered, with only
about 20 reported cases [1]. Herein, we report a case of
alcohol-induced acute pancreatitis, followed by HUS which
was successfully managed with continuous renal replace-
ment therapy (CRRT), highlighting the importance of early
diagnosis and prompt initiation of CRRT.Case presentation
A previously healthy 38-year-old female, non-smoker and
non-alcoholic, was hospitalized following acute alcohol in-
toxication. She had drunk more than 500 ml of alcohol in
about 2 hours and subsequently lost consciousness. Prior
to losing consciousness she complained of severe epigastric* Correspondence: fupeng1966@qq.com
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reproduction in any medium, provided the orpain and frequent vomiting. On admission, serum creatin-
ine, blood urea nitrogen (BUN), hemoglobin, white blood
cell (WBC) count, electrolytes, and liver function tests
were within normal ranges. Serum amylase was 1728 IU/L
(normal, < 100 IU/L). Ultrasound revealed the body and
tail of the pancreas to be edematous, the biliary tree was
not dilated, and there was sludge in the gallbladder. Ab-
dominal computed tomography (CT) revealed an edema-
tous pancreas with necrotic tissue in the left parieto-colic
area. The diagnosis was alcohol-induced acute pancreatitis.
During the next 2 days her renal function progressively
deteriorated, and her urine output decreased to < 400 ml
per 24 hours. On the third day of admission her urea and
creatinine were 12.8 mmol/L (normal range: 4.5-6.7 mmol/
L) and 420 μmol/L (normal range: 50–110 μmol/L), re-
spectively. Her hemoglobin level had dropped from 14.9 g/
dL to 8.8 g/dL, with a reticulocyte count of 75,000/mm3
(normal range: 25,000-120,000/mm3), her platelet count
was 32 × 109/L (normal range: 100-300 × 109/L), and hapto-
globin was 0.05 g/L (normal range: 0.2-2.4 g/L). Peripheral
blood smear revealed schistocytes, and the Coombs’ testThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was normal, and her prothrombin time international
normalized ratio (PT-INR) was 1.5-2.5. Early in the dis-
ease course plasma LDH is elevated in patient (856U/L,
compared to normal LDH level: 35-123U/L), and LDH
levels gradually decline with CRRT treatment and mitiga-
tion of pancreatitis. Her clinical symptoms of acute kidney
injury and her treatment reaction were not consistent with
a diagnosis of DIC. Renal biopsy was not performed be-
cause the patient refused invasive examinations. A diagno-
sis of HUS was made, and she was transferred to the
intensive care unit (ICU).
She received daily continuous renal replacement therapy
(CRRT) by hemofiltration on the third through the fifth
hospital days, and then every other day for a total of 13
treatments. CRRT was administered at a dosage of 40 ml/
kg/h for a duration of 6–8 hours, and the volume of fluid
removed varied from 500 to 2500 ml. She also received
intermittent transfusions of fresh frozen plasma. Her urine
volume increased beginning of the fifth hospital day, and
her serum amylase level returned to the normal range by
hospital day 7. Her renal function progressively improved,
and she was transferred from the ICU to the general ward
on day 20. She was discharged 1 month after admission in
good condition, and follow-up at 3 months revealed nor-
mal urea and creatinine (5.2 mmol/L and 69 μmol/L, re-
spectively), and her platelet count was 129 × 109/L. A year
and 3months later, she gave birth to a healthy boy.
Conclusions
Hemolytic uremic syndrome is characterized by non-
immune hemolytic anemia, thrombocytopenia, and renal
failure caused by platelet thrombi in the microcircula-
tion of the kidney and other organs [2]. The disease is
not uncommon in children, where approximately 80% of
the cases are associated with E. coli O157:H7 infection
and 80-90% of cases resolve without squelae [3]. HUS is
rare in adults, and the overall prognosis in adults is poor
with a reported mortality of up to 90% if not treated,
and a rate of chronic renal failure of 40-60% [2,3].
The etiology of HUS following pancreatitis is not clearly
understood, as there are only about 20 cases reported in
the literature [1]. Our case and previously reported cases
suggest that the acute inflammatory response to pancrea-
titis may trigger the onset of HUS [1]. Silva [4] hypothe-
sized that the release of inflammatory mediators such as
tumor necrosis factor (TNF)-alpha and interleukin (IL)-1
during an acute episode of pancreatitis may induce wide-
spread vascular endothelial injury. It has also been sug-
gested that modification of circulating von Willebrand
factor (VWF) by pancreatic proteases leads to platelet
aggregation [4,5]. The release of ultralarge VWF multi-
mers from endothelial cells during inflammation, and
the inhibition of the VWF cleaving protease ADAMTS-13by cytokines have also been suggested as a contributory
mechanism of HUS [6].
The treatment of HUS following acute pancreatitis is
primarily supportive. Fresh frozen plasma infusion may
improve the renal outcome in adult HUS [2], and ex-
change plasmapheresis has been reported to be an effect-
ive treatment with a response rate of 79% [7]. However, in
patients with relapsing or refractory HUS with or without
ADAMTS-13 deficiency, plasma exchange is often unsuc-
cessful [8]. Rituximab, a chimeric monoclonal antibody di-
rected against CD20 antigen expressed by B lymphocytes,
has shown promise as a treatment option [8,9]. At the time
the patient was seen and treated plasmapheresis was not
available (treatment was carried out before dawn and CRRT
was performed in the emergency department), and because
CRRT therapy was very effective performing plasmapher-
esis was not considered necessary.
In renal replacement therapy (RRT) performed via hemo-
filtration, solute movement is governed by convection and
unlike in dialysis a dialysate is not used [10]. Positive hydro-
static pressure causes water and solutes to migrate across a
filter membrane from the blood to the filtrate compart-
ment, where it is drained. An isotonic replacement fluid is
added to the blood to replace fluid volume and electrolytes.
Treatments can be given intermittently, or continuously.
CRRT has proven to be particularly useful in the treatment
of renal failure as it can help in restoration of acid–base im-
balances and electrolyte abnormalities, maintain hemody-
namic stability, and allows the adjustment drug dosages to
prevent drug accumulation and overdose [10]. In addition,
it can remove metabolic waste products and clear inflam-
matory mediators such as IL-1, IL-6, IL-8. It is possible that
removal of inflammatory mediators by the rapid initiation
of CRRT contributed to the recovery of our patient, though
we have no clear evidence to support this hypothesis.
In summary, we have presented a case of adult HUS
secondary to acute pancreatitis successfully managed by
prompt diagnosis and rapid initiation of CRRT via hemo-
filtration before severe kidney injury or renal failure had
occurred. Prior case reports and our case should remind
clinicians that HUS is a possible complication of acute
pancreatitis. Early institution of CRRT may be an effective
treatment to prevent mortality and improve outcomes.
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